Publicacions en col·laboració amb investigadors/es de Hospital San Pedro (19)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 20, Núm. 3, pp. 329-334

  2. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  3. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy

    Journal of Viral Hepatitis, Vol. 21, Núm. 7, pp. 475-479

  2. Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions

    PLoS ONE, Vol. 9, Núm. 12

  3. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  4. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2011

  1. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse

    AIDS, Vol. 25, Núm. 8, pp. 1131-1133

2010

  1. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study

    The Lancet, Vol. 376, Núm. 9738, pp. 340-345

  2. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C virus coinfected patients with prior nonresponse or relapse

    Journal of Acquired Immune Deficiency Syndromes, Vol. 53, Núm. 3, pp. 364-368

2009

  1. Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality

    Current HIV Research, Vol. 7, Núm. 2, pp. 224-230

2007

  1. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

    Journal of Infectious Diseases, Vol. 196, Núm. 5, pp. 670-676

2005

  1. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine

    AIDS, Vol. 19, Núm. 6, pp. 569-575

  2. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial

    Antiviral Therapy, Vol. 10, Núm. 7, pp. 825-832

2003

  1. Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes

    HIV Clinical Trials, Vol. 4, Núm. 6, pp. 372-381

2002

  1. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir

    AIDS, Vol. 16, Núm. 14, pp. 1964-1966